Early bird offer: Save £400 if you register before Friday 26th July!
Choosing which clinically relevant drug transporters to study is not straightforward. Having said this, knowing which are necessary for regulatory approval and which are simply ‘nice to haves’ can save you time and money. These assessments will become even more complex with the emerging transporters recommended by the ITC this year, for early and late-phase testing.
This September, over 50 industry, academic and regulatory experts will gather in London for Pharma IQ's Clinically Relevant Drug Transporters Conference. Senior representatives from the International Transporter Consortium, Pfizer Neusentis, GlaxoSmithKline, Roche and AstraZeneca will share best practice methods to assist you when making these challenging decisions.
I am pleased to announce that ALL the topics in the 2013 ITC white papers will be covered by those at the sharp end of drug development.
Key case studies include:
In vitro–in vivo extrapolation and PK best practices
Clinical modulation of efflux transport at the blood-brain barrier
Transporter pharmacogenomics and the impact of polymorphisms on patient stratification
Rationally predicting drug disposition and clinically relevant DDIs
Calibrating different cell lines for drug-drug interaction studies.
For more information please:
Call: +44 (0) 207 036 1300
Download the agenda: http://bit.ly/10NjMlV
On Monday September 16, 2013 at 9:00 am, ends Wednesday September 18, 2013 at 5:00 pm.